Multiple sclerosis trials recruiting in Alabama

All Multiple sclerosis trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Cullman, Huntsville, Mobile
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
  NCT06782490 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Birmingham
• AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
  NCT04721717 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham
• Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
  NCT03759522 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham
• Care in Multiple Sclerosis (MS)
  NCT07011914 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Alabama: Cullman, Homewood
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Birmingham
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  NCT05104983 · Phase: Phase 2 · Ages: 1 Day to 6 Months · Sex: All (male and female) · Alabama: Birmingham
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham, Cullman
• TSC Biosample Repository and Natural History Database
  NCT05676099 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Alabama: Birmingham
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham